[177Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 study

S Sandhu; AM Joshua; L Emmett; M Bressel; A Anton; L Spain; LG Horvath; A Pasam; SH Tolmeijer; TJ Akhurst; R Alipour; P Banks; JP Buteau; E Cassidy; M Crumbaker; N Dhiantravan; W Xu; J Chan; N Hitchen; M Scalzo; AS Ravi Kumar; G Kong; R Wallace; N Williams; S Williams; NM Haynes; P Neeson; AW Wyatt; RJ Hicks; MS Hofman

Journal article

[177Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 study

S Sandhu, AM Joshua, L Emmett, M Bressel, A Anton, L Spain, LG Horvath, A Pasam, SH Tolmeijer, TJ Akhurst, R Alipour, P Banks, JP Buteau, E Cassidy, M Crumbaker, N Dhiantravan, W Xu, J Chan, N Hitchen, M Scalzo Show all

Lancet Oncology | Published : 2026

DOI: 10.1016/S1470-2045(26)00017-3

Open access

Abstract

Background Lutetium-177 [177Lu]-prostate-specific membrane antigen (PSMA)-617 improves overall survival and progression-free survival in metastatic castration resistant prostate cancer (mCRPC), whereas immune checkpoint inhibitors (ICIs) have limited activity. Preclinical evidence suggests radioligand therapy might induce immunogenic cell death that can be enhanced with ICIs. This study evaluates the activity and adverse event profile associated with multiple doses of [177Lu]Lu-PSMA-617 with pembrolizumab. Methods PRINCE was a multicentre, single-arm, phase 1b/2 trial of [177Lu]Lu-PSMA-617 and pembrolizumab. Eligible participants were aged 18 years or older, had mCRPC, an Eastern Cooperative..

View full abstract